nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-182-10-88-95nogr-1455Research ArticleОБЗОРREVIEWКардиоваскулярная коморбидность при неалкогольной жировой болезни печениCardiovascular comorbidity in non-alcoholic fatty liver diseaseТимаковаА. Ю.TimakovaA. Yu.

студент 4 курса лечебного факультета

 г. Омск, ул. Ленина, 12, Россия

СкирденкоЮ. П.SkirdenkoYu. P.

ассистент кафедры факультетской терапии, профессиональных болезней, кандидат медицинский наук

 г. Омск, ул. Ленина, 12, Россия

julija-loseva1@yandex.ruhttps://orcid.org/0000-0002-6581-7017ЛивзанМ. А.LivzanM. A.

ректор, заведующий кафедрой факультетской терапии, профессиональных болезней, профессор, д. м. н.

Scopus Author ID: 24341682600

 г. Омск, ул. Ленина, 12, Россия

D. Sci. (Med.), Professor, Rector, Head of the Department of Faculty Therapy, Occupational Diseases

Scopus Author ID: 24341682600 Russian Federation, Omsk, Lenin street, 12, Russia

КролевецТ. С.KrolevetsT. S.

ассистент кафедры факультетской терапии, профессиональных болезней, кандидат медицинский наук

 г. Омск, ул. Ленина, 12, Россия

НиколаевН. А.NikolaevN. A.

профессор кафедры факультетской терапии, профессиональных болезней, доцент, д. м. н.

 г. Омск, ул. Ленина, 12, Россия

НелидоваА. В.NelidovaA. V.

доцент кафедры пропедевтики внутренних болезней, доцент, кандидат медицинский наук

 г. Омск, ул. Ленина, 12, Россия

Russian Federation, Omsk, Lenin street, 12, Russia

Федеральное государственное бюджетное образовательное учреждение высшего образования «Омский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияFederal State Funded Educational Institution for Higher Education Omsk State Medical University Ministry of Public HealthRussian Federation2020281020200108895Copyright © Тимакова А.Ю., Скирденко Ю.П., Ливзан М.А., Кролевец Т.С., Николаев Н.А., Нелидова А.В., 20202020Тимакова А.Ю., Скирденко Ю.П., Ливзан М.А., Кролевец Т.С., Николаев Н.А., Нелидова А.В.Timakova A.Y., Skirdenko Y.P., Livzan M.A., Krolevets T.S., Nikolaev N.A., Nelidova A.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/1455неалкогольная жировая болезнь печенисердечно-сосудистые заболеванияартериальная гипертензиясердечная недостаточностьнарушения ритмаишемическая болезнь сердцаnon-alcoholic fatty liver diseasecardiovascular diseasearterial hypertensionheart failurerhythm disorderscoronary heart diseaseИсточник финансирования: Грант Президента РФ для государственной поддержки ведущих научных школ (НШ-2558.2020.7) (соглашение № 075–15–2020–036 от 17 марта 2020 года) «Разработка технологии здоровьесбережения коморбидного больного гастроэнтерологического профиля на основе контроля приверженности».ReferencesНаумова Л.А., Осипова О. Н. Коморбидность: механизмы патогенеза, клиническое значение. Современные проблемы науки и образования. – 2016, 5, стр. 57–64.Naumova L. A., Osipova O. N. Comorbidity: mechanisms of pathogenesis, clinical significance. Modern problems of science and education. 2016. No. 5, pp. 57–64.Самородская И.В., Болотова Е. В. Терминологические и демографические аспекты коморбидности. Успехи Геронтологии. –2016, 29, 3, стр. 471.I. V. Samorodskaya, E. V. Bolotova. Terminological and demographic aspects of comorbidity. Advances in Gerontology. 2016;29(3):471.Драпкина О. М., Шутов А. М., Ефремова Е. В. Коморбидность, мультиморбидность, двойной диагноз – синонимы или разные понятия? Кардиоваскулярная терапия и профилактика, 2019. –18, 2, стр. 65–69 doi: 10.15829/1728–8800–2019–2–65–69.Drapkina O. M., Shutov A. M., Efremova E. V. Comorbidity, multimorbidity, dual diagnosis – synonyms or different concepts? Cardiovascular therapy and prevention. 2019;18(2):65–69. doi: 10.15829 / 1728–8800–2019–2–65–69.Оганов Р.Г., Симаненков В. И., Бакулин И. Г., Бакулина Н. В. и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019, 18. –1. стр. 5–66. doi: 10.15829/1728–8800–2019–1–5–66.Oganov R. G., Simanenkov V. I., Bakulin I. G., Bakulina N. V. et al. Comorbid pathology in clinical practice. Diagnostic and treatment algorithms. Cardiovascular therapy and prevention. 2019;18(1):5–66. doi: 10.15829/1728–8800–2019–1–5–66Тирикова О.В., Козлова Н. М., Елисеев С. М., Гумеров Р. Р. Неалкогольная жировая болезнь печени и ее роль в развитии сердечно-сосудистых заболеваний. Сибирский медицинский журнал (Иркутск), 2015. –1, стр. 30–36.Tirikova O. V., Kozlova N. M., Eliseev S. M., Gumerov R. R. Non-alcoholic fatty liver disease and its role in the development of cardiovascular diseases. Siberian medical journal (Irkutsk). 2015, 1, pp. 30–36.Лаптева Е.А., Козлова И. В. Молекулярно-генетические предпосылки коморбидности жировой болезни печени и патологии толстой кишки (обзор). Саратовский научно-медицинский журнал, 2017. –13, 1, стр. 29–34.Lapteva E. A., Kozlova I. V. Molecular genetic prerequisites for the comorbidity of fatty liver disease and colon pathology (review). Saratov Journal of Medical Scientific Research. 2017;13(1).:29–34.Parise E. R. Nonalcoholic fatty liver disease (NAFLD), more than a liver disease NASH. Arquivos de Gastroenterologia. 2019;56(3)243–245. doi: 10.1590/s0004–2803.201900000–45Parise E. R. Nonalcoholic fatty liver disease (NAFLD), more than a liver disease NASH. Arquivos de Gastroenterologia. 2019;56(3)243–245. doi: 10.1590/s0004–2803.201900000–45Ахмедов В. А. Взаимосвязь сердечно-сосудистых осложнений и неалкогольной жировой болезни печени. РМЖ, 2018. –1(2), стр. 86–88.Akhmedov V. A. The relationship of cardiovascular complications and non-alcoholic fatty liver disease. RMZh. 2018;1 (2):86–88.Лазебник Л. Б., Радченко В. Г., Голованова Е. В. и др. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение (рекомендации для терапевтов, 2-я версия).. Терапия, 2017, 3, 13. – стр. 6–23.Lazebnik L. B., Radchenko V. G., Golovanova E. V. et al. Non-alcoholic fatty liver disease: clinical picture, diagnosis, treatment (recommendations for therapists, 2nd version). Therapy. 2017;3(13):6–23.Ивашкин В. Т. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. РЖГГК- 2015. – 6, стр. 31–41.Ivashkin V. T. and others. Prevalence of non-alcoholic fatty liver disease in outpatient patients in the Russian Federation: results of the DIREG 2 study. RZHGGK-2015, 6, pp. 31–41.Драпкина О. М., Корнеева О. Н. Континуум неалкогольной жировой болезни печени: от стеатоза печени до сердечно-сосудистого риска. Рациональная Фармакотерапия в Кардиологии, 2016. –12, 4, стр. 424–429 doi: 10.20996/1819–6446–2016–12–4–424–429.Drapkina O. M., Korneeva O. N. The continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Rational Pharmacotherapy in Cardiology. 2016;12(4):424–429 doi: 10.20996 / 1819–6446–2016–12–4–424–429Свистунов А. А., Осадчук М. А., Киреева Н. В., Осадчук М. М. Оптимизация терапии заболеваний печени, не ассоциированных с вирусной инфекцией. Терапевтический архив, 2018, 90,2. – 94– 99. doi: 10.26442/terarkh2018902105–111.Svistunov A. A., Osadchuk M. A., Kireeva N. V., Osadchuk M. M. Optimization of therapy for liver diseases not associated with viral infection. Therapeutic archive. 2018;90(2):94–99. doi: 10.26442/terarkh2018902105–111Ахмедов В. А., Мамедова Н. Ф., Гаус О. В. Неалкогольная жировая болезнь печени и коморбидность. Гастроэнтерология Санкт-Петербурга, 2019, 3, 4, стр. 47–52.Akhmedov V. A., Mamedova N. F., Gaus O. V. Non-alcoholic fatty liver disease and comorbidity. Gastroenterology of St. Petersburg. 2019;3(4):47–52.Mangi M A, Rehman H, Minhas A M, et al. Non-Alcoholic Fatty Liver Disease Association with Cardiac Arrhythmias. Cureus. 2017;9(4)1–8. doi: 10.7759/cureus.1165Mangi M A, Rehman H, Minhas A M, et al. Non-Alcoholic Fatty Liver Disease Association with Cardiac Arrhythmias. Cureus. 2017;9(4)1–8. doi: 10.7759/cureus.1165Плотникова Е. Ю. Дислипидемия при неалкогольной жировой болезни печени как маркер сердечно-сосудистого риска. РМЖ. Медицинское обозрение, 2019. – 1, 2, стр. 64–69.Plotnikova E. Yu. Dyslipidemia in non-alcoholic fatty liver disease as a marker of cardiovascular risk. RMZh. Medical Review. 2019;1(2):64–69.Tracey G. S., Maria Esther Perez Trejo, McClelland R., Bradley R. et al. Circulating Interleukin-6 is a Biomarker for Coronary Atherosclerosis in Nonalcoholic Fatty Liver Disease: Results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol. 2018;129(1) 77–86. doi: 10.1161/CIRCULATIONAHA.113.003625.DyslipidemiaTracey G. S., Maria Esther Perez Trejo, McClelland R., Bradley R. et al. Circulating Interleukin-6 is a Biomarker for Coronary Atherosclerosis in Nonalcoholic Fatty Liver Disease: Results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol. 2018;129(1) 77–86. doi: 10.1161/CIRCULATIONAHA.113.003625.DyslipidemiaMusso G., Gambino R., Cassader M., Pagano G. Metaanalysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of noninvasive tests for liver disease severity. Annals of medicine. 2011, no.43, pp. 617–649. doi: 10.3109/07853890.2010.518623Musso G., Gambino R., Cassader M., Pagano G. Metaanalysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of noninvasive tests for liver disease severity. Annals of medicine. 2011, no.43, pp. 617–649. doi: 10.3109/07853890.2010.518623Широкова Е. Н. Неалкогольная жировая болезнь печени, гиперлипидемия и сердечно-сосудистые риски. Consilium Medicum. – 2017, 19, 8.2. – стр. 74–76 doi: 10.26442/2075–1753_19.8.2.74–76.Shirokova E. N. Non-alcoholic fatty liver disease, hyperlipidemia and cardiovascular risks. Consilium Medicum. 2017;19(8.2):74–76 doi: 10.26442 / 2075–1753_19.8.2.74–76Tana C., Ballestri S., Ricci F., Di Vincenzo A., Ticinesi A. et al. Cardiovascular risk in non-alcoholic fatty liver disease: Mechanisms and therapeutic implications. International Journal of Environmental Research and Public Health. 2019;16(17):1–19. doi: 10.3390/ijerph16173104Tana C., Ballestri S., Ricci F., Di Vincenzo A., Ticinesi A. et al. Cardiovascular risk in non-alcoholic fatty liver disease: Mechanisms and therapeutic implications. International Journal of Environmental Research and Public Health. 2019;16(17):1–19. doi: 10.3390/ijerph16173104Perera N. et al. Non-alcoholic fatty liver disease increases the mortality from acute coronary syndrome: An observational study from Sri Lanka. BMC Cardiovascular Disorders, 2016, 16, 1, стр. 4–9. doi: 10.1186/s12872–016–0212–8;Perera N. et al. Non-alcoholic fatty liver disease increases the mortality from acute coronary syndrome: An observational study from Sri Lanka. BMC Cardiovascular Disorders, 2016, 16, 1, стр. 4–9. doi: 10.1186/s12872–016–0212–8;Sirbu O. et al. Non-alcoholic fatty liver disease-From the cardiologist perspective. Anatolian Journal of Cardiology. 2016;16(7): 534–541. doi: 10.14744/AnatolJCardiol.2016.7049Sirbu O. et al. Non-alcoholic fatty liver disease-From the cardiologist perspective. Anatolian Journal of Cardiology. 2016;16(7): 534–541. doi: 10.14744/AnatolJCardiol.2016.7049Liu H., Cao Y., Sun D. et al. Impact of non-alcoholic fatty liver disease on cardiovascular outcomes in patients with stable coronary artery disease: A matched case–control study. Clinical and Translational Gastroenterology. 2019, 10(2): 1–8. doi: 10.14309/ctg.0000000000000011Liu H., Cao Y., Sun D. et al. Impact of non-alcoholic fatty liver disease on cardiovascular outcomes in patients with stable coronary artery disease: A matched case–control study. Clinical and Translational Gastroenterology. 2019, 10(2): 1–8. doi: 10.14309/ctg.0000000000000011Liu Y., Zhong G., Tan H. et al. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Scientific reports, 2019;9(1):1–10. doi: 10.1038/s41598–019–47687–3Liu Y., Zhong G., Tan H. et al. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Scientific reports, 2019;9(1):1–10. doi: 10.1038/s41598–019–47687–3Baharvand-Ahmadi B., Sharifi K., Namdari M. Prevalence of non-alcoholic fatty liver disease in patients with coronary artery disease. ARYA Atherosclerosis, 2016; 12(4):201–205Baharvand-Ahmadi B., Sharifi K., Namdari M. Prevalence of non-alcoholic fatty liver disease in patients with coronary artery disease. ARYA Atherosclerosis, 2016; 12(4):201–205Alkagiet S., Papagiannis A., Tziomalos K. Associations between nonalcoholic fatty liver disease and ischemic stroke. World J Hepatol, 2018;10(7):474–478. doi: 10.4254/wjh.v10.i7.474Alkagiet S., Papagiannis A., Tziomalos K. Associations between nonalcoholic fatty liver disease and ischemic stroke. World J Hepatol, 2018;10(7):474–478. doi: 10.4254/wjh.v10.i7.474Ismaiel A., Colosi H., Rusu F. et al. Cardiac arrhythmias and electrocardiogram modifications inon-alcoholic fatty liver disease. A systematic review. Journal of Gastrointestinal and Liver Diseases, 2019;28(4):483–493. doi: 10.15403/jgld-344Ismaiel A., Colosi H., Rusu F. et al. Cardiac arrhythmias and electrocardiogram modifications inon-alcoholic fatty liver disease. A systematic review. Journal of Gastrointestinal and Liver Diseases, 2019;28(4):483–493. doi: 10.15403/jgld-344Athyros V. G., Tziomalos K., Katsiki N., Doumas M. et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.. World Journal of Gastroenterology, 2015;21(22): 6820–6834. doi: 10.3748/wjg.v21.i22.6820Athyros V. G., Tziomalos K., Katsiki N., Doumas M. et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.. World Journal of Gastroenterology, 2015;21(22): 6820–6834. doi: 10.3748/wjg.v21.i22.6820Лазебник Л. Б., Радченко В. Г., Голованова Е. В. и др. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение (рекомендации для терапевтов). Терапия, 2016. –2, 6, стр. 6–18.Lazebnik L. B., Radchenko V. G., Golovanova E. V. et al. Non-alcoholic fatty liver disease: clinical picture, diagnosis, treatment (recommendations for therapists). Therapy. 2016;2(6):6–18.Fotbolcu H., Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World Journal of Gastroenterology, 2016;22(16):4079–4090. doi: 10.3748/wjg.v22.i16.4079Fotbolcu H., Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World Journal of Gastroenterology, 2016;22(16):4079–4090. doi: 10.3748/wjg.v22.i16.4079Ismaiel A. et al. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis – Literature Review. Frontiers in Medicine. 2019, 6, pp. 1–18. doi: 10.3389/fmed.2019.00202Ismaiel A. et al. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis – Literature Review. Frontiers in Medicine. 2019, 6, pp. 1–18. doi: 10.3389/fmed.2019.00202Ливзан М. А., Гаус О. В., Николаев Н. А. Кролевец Т. С. НАЖБП: коморбидность и ассоциированные заболевания. Экспериментальная и клиническая гастроэнтерология, 2019, 170, 10, стр. 57–65 doi: 10.31146/1682–8658-ecg-170–10–57–65.Livzan M. A., Gaus O. V., Nikolaev N. A., Krolevetz T. S. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology. 2019;1(10):57–65. (In Russ.) https://doi.org/10.31146/1682–8658-ecg-170–10–57–65Abenavoli L., Milic N., Di Renzo L. et al. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2016, no.22, pp. 7006–7016. doi: 10.3748/wjg.v22.i31.7006Abenavoli L., Milic N., Di Renzo L. et al. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2016, no.22, pp. 7006–7016. doi: 10.3748/wjg.v22.i31.7006Ливзан М. А., Лаптева И. В., Миллер Т. С. Роль лептина и лептинорезистентности в формировании неалкогольной жировой болезни печени у лиц с ожирением и избыточной массой тела. Экспериментальная и клиническая гастроэнтерология. – 2014. – 8 (108), стр. 27–33.Livzan MA, Lapteva IV, Miller TS. [Role of leptin and leptin resistance in non-alcoholic fatty liver disease development in persons with obesity and overweight]. Eksp Klin Gastroenterol. 2014;(8):27–33. Russian. PMID: 25911909.Heiker J. T., Kosel D., Beck-Sickinger A. G. Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Biol Chem, 2010, no. 391, pp. 1005–1018. doi: 10.1515/BC.2010.104Heiker J. T., Kosel D., Beck-Sickinger A. G. Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Biol Chem, 2010, no. 391, pp. 1005–1018. doi: 10.1515/BC.2010.104Polyzos S. A., Aronis K. N., Kountouras J., Raptis D. D., Vasiloglou M. F., Mantzoros C. S. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia, 2016, no.59, pp. 30–43. doi: 10.1007/s00125–015–3769–3Polyzos S. A., Aronis K. N., Kountouras J., Raptis D. D., Vasiloglou M. F., Mantzoros C. S. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia, 2016, no.59, pp. 30–43. doi: 10.1007/s00125–015–3769–3Bekaert M., Verhelst X., Geerts A., Lapauw B., Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016, no.17, pp. 68–80. doi: 10.1111/obr.12333Bekaert M., Verhelst X., Geerts A., Lapauw B., Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016, no.17, pp. 68–80. doi: 10.1111/obr.12333Brouwers M., Simons N., Stehouwer C. et al. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia, 2020, 63, no. 2, pp. 253–260. doi: 10.1007/s00125–019–05024–3Brouwers M., Simons N., Stehouwer C. et al. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia, 2020, 63, no. 2, pp. 253–260. doi: 10.1007/s00125–019–05024–3Tracey G. S., Maria Esther Perez Trejo, McClelland R., Bradley R. et al. Circulating Interleukin-6 is a Biomarker for Coronary Atherosclerosis in Nonalcoholic Fatty Liver Disease: Results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol, 2018;129(1);77–86. doi: 10.1161/CIRCULATIONAHA.113.003625.DyslipidemiaTracey G. S., Maria Esther Perez Trejo, McClelland R., Bradley R. et al. Circulating Interleukin-6 is a Biomarker for Coronary Atherosclerosis in Nonalcoholic Fatty Liver Disease: Results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol, 2018;129(1);77–86. doi: 10.1161/CIRCULATIONAHA.113.003625.DyslipidemiaXu Y., Zhao Z., Liu S. et al. Association of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease with FADS2 rs3834458 Gene Polymorphism in the Chinese Han Population. Gastroenterology Research and Practice, 2019, pp. 1–7. doi: 10.1155/2019/6069870Xu Y., Zhao Z., Liu S. et al. Association of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease with FADS2 rs3834458 Gene Polymorphism in the Chinese Han Population. Gastroenterology Research and Practice, 2019, pp. 1–7. doi: 10.1155/2019/6069870Оганов Р. Г., Симаненков В. И., Бакулин И. Г. и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019, 18, 1, стр. 5–66. doi: 10.15829/1728–8800–2019–1–5–66.Oganov R. G., Simanenkov V. I., Bakulin I. G., et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5–66. (In Russ.) https://doi.org/10.15829/1728–8800–2019–1–5–66Драпкина О. М., Яфарова А. А. Неалкогольная жировая болезнь печени и сердечно-сосудистый риск: состояние проблемы.. Рациональная фармакотерапия в кардиологии, 2017, 13, 5. – стр. 645–650 doi: 10.20996/1819–6446–2017–13–5–645–650Drapkina O. M., Yafarova A. A. Non-alcoholic fatty liver disease and cardiovascular risk: scientific problem state. Rational Pharmacotherapy in Cardiology. 2017;13(5):645–650. (In Russ.) https://doi.org/10.20996/1819–6446–2017–13–5–645–650Журавлёва А. К. Неалкогольная жировая болезнь печени как предиктор сердечно-сосудистых заболеваний и сахарного диабета 2 типа. Экспериментальная и клиническая гастроэнтерология, 2019, 165, 5. – стр. 144–149 doi: 10.31146/1682–8658-ecg-165–5–144–149Zhuravlyova A. K. Non-alcoholic fatty liver disease as a predictor of cardiovascular diseases and type 2 diabetes. Experimental and Clinical Gastro entero logy. 2019;(5):144–149. (In Russ.) https://doi.org/10.31146/1682–8658-ecg-165–5–144–149Zhang Y., Xu J., Wang J. et al. Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease. BMC Genomics. 2019;20(1);1–12. doi: 10.1186/s12864–019–6251–7Zhang Y., Xu J., Wang J. et al. Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease. BMC Genomics. 2019;20(1);1–12. doi: 10.1186/s12864–019–6251–7Lazar V., Ditu L. M., Pircalabioru G. G., Picu A., Petcu L., Cucu N., Chifiriuc M. C. Gut Microbiota, Host Organism, and Diet Trialogue in Diabetes and Obesity. Front. Nutr. 2019;6(21):1–20. doi: 10.3389/fnut.2019.00021Lazar V., Ditu L. M., Pircalabioru G. G., Picu A., Petcu L., Cucu N., Chifiriuc M. C. Gut Microbiota, Host Organism, and Diet Trialogue in Diabetes and Obesity. Front. Nutr. 2019;6(21):1–20. doi: 10.3389/fnut.2019.00021Драпкина О. М. Печень и атеросклероз. Гастроэнтерология. Эффективная фармакотерапия, 2015, 4, стр. 14–20.Drapkina O. M. Liver and atherosclerosis. Gastroenterology. Effective pharmacotherapy. 2015, No. 4, pp. 14–20.Sao R., Aronow W. Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Arch Med Sci, 2018, no.6, pp. 1233–1244. doi: 10.5114/aoms.2017.68821Sao R., Aronow W. Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Arch Med Sci, 2018, no.6, pp. 1233–1244. doi: 10.5114/aoms.2017.68821И. Г. Бакулин, М. П. Абациева, М. И. Скалинская, М. С. Журавлева. Клиническое и медико-социальное значение НАЖБП через призму коморбидности. Терапия, 2019, 6, 32, стр. 76–86 doi: 10.18565I. G. Bakulin, M. P. Abatsiev, M. I. Skalinskaya, M. S. Zhuravleva. Clinical and medico-social significance of NAFLD through the prism of comorbidity. Therapy. 2019;6(32):76–86. doi: 10.18565Aronow W. Nonalcoholic fatty liver disease is associated with coronary artery disease and subclinical atherosclerosis. Future Cardiology, 2016; 2(4): 393–396. doi: 10.2217/fca-2016–0033Aronow W. Nonalcoholic fatty liver disease is associated with coronary artery disease and subclinical atherosclerosis. Future Cardiology, 2016; 2(4): 393–396. doi: 10.2217/fca-2016–0033Chandra A., Li W., Stone C. et al. The cerebral circulation and cerebrovascular disease I: Anatomy. Brain circulation. Brain Circulation, 2017;3(1):35–40. doi: 10.4103/bc.bcChandra A., Li W., Stone C. et al. The cerebral circulation and cerebrovascular disease I: Anatomy. Brain circulation. Brain Circulation, 2017;3(1):35–40. doi: 10.4103/bc.bcDinani A., Sanyal A. Nonalcoholic fatty liver disease: Implications for cardiovascular risk. Cardiovascular Endocrinolog y, 2017;6(2);62–72. doi: 10.1097/XCE.0000000000000126Dinani A., Sanyal A. Nonalcoholic fatty liver disease: Implications for cardiovascular risk. Cardiovascular Endocrinolog y, 2017;6(2);62–72. doi: 10.1097/XCE.0000000000000126Назарова М. Б. Артериальная гипертензия и неалкогольная жировая болезнь печени// Фундаментальные и прикладные научные исследования, 2019, стр.173–174.Nazarova M. B. Arterial hypertension and non-alcoholic fatty liver disease. Fundamental and applied scientific research. 2019, pp. 173–174.Li H, Hu B, Wei L, Zhou L, Zhang L, Lin Y, Qin B, Dai Y, Lu Z. Non-alcoholic fatty liver disease is associated with stroke severity and progression of brainstem infarctions. Eur J Neurol. 2018, no. 25, pp. 577. doi: 10.1111/ene.13556Li H, Hu B, Wei L, Zhou L, Zhang L, Lin Y, Qin B, Dai Y, Lu Z. Non-alcoholic fatty liver disease is associated with stroke severity and progression of brainstem infarctions. Eur J Neurol. 2018, no. 25, pp. 577. doi: 10.1111/ene.13556Käräjämäki A. J., Pätsi O. P., Savolainen M., Kesäniemi Y. A., Huikuri H., Ukkola O. Non- Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). PLoS ONE, 2015;10(11):1–13. doi:10.1371/journal.pone.0142937Käräjämäki A. J., Pätsi O. P., Savolainen M., Kesäniemi Y. A., Huikuri H., Ukkola O. Non- Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). PLoS ONE, 2015;10(11):1–13. doi:10.1371/journal.pone.0142937Fargion S., Porzio M., Fracanzani A. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World Journal of Gastroenterology, 2014;20(37): 13306–13324 doi: 10.3748/wjg.v20.i37.13306Fargion S., Porzio M., Fracanzani A. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World Journal of Gastroenterology, 2014;20(37): 13306–13324 doi: 10.3748/wjg.v20.i37.13306Серов И. С., Блохина И. И., Шагина В. Н. Неалкогольная жировая болезнь печени как фактор риска сердечно-сосудистых заболеваний. Молодой ученый. – 2019, 37, 275, стр. 112–114.Serov I. S., Blokhina I. I., Shagina V. N. Non-alcoholic fatty liver disease as a risk factor for cardiovascular diseases. Young scientist. 2019;37(275): 112–114.Wójcik-Cichy K., Koślińska-Berkan K., Piekarska A. The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases. Clin Exp HEPATOL. 2018;4(1);1–6. doi: 10.5114/ceh.2018.73155Wójcik-Cichy K., Koślińska-Berkan K., Piekarska A. The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases. Clin Exp HEPATOL. 2018;4(1);1–6. doi: 10.5114/ceh.2018.73155Ховасова Н. О., Верткин А. Л. Сосудистая коморбидность – новый тренд в амбулаторном звене. Терапия, 2015, 1, 1, стр. 38–44.Khovasova N. O., Vertkin A. L. Vascular comorbidity – a new trend in the outpatient department. Therapy. 2015;1(1):38–44.Golabi P., Fukui N., Paik J., Sayiner M., Mishra A., Younossi Z. Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2019;3(8):1050–1060. doi: 10.1002/hep4.1387Golabi P., Fukui N., Paik J., Sayiner M., Mishra A., Younossi Z. Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2019;3(8):1050–1060. doi: 10.1002/hep4.1387Zhang Z., Wang P., Guo F. et al. Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features and relevance. Journal of International Medical Research. 2018;46(9):3959–3969. doi: 10.1177/0300060518782780Zhang Z., Wang P., Guo F. et al. Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features and relevance. Journal of International Medical Research. 2018;46(9):3959–3969. doi: 10.1177/0300060518782780Bellentani S., Dalle G. R., Suppini A., Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology. 2008, no.47, pp. 746–754. doi: 10.1002/hep.22009Bellentani S., Dalle G. R., Suppini A., Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology. 2008, no.47, pp. 746–754. doi: 10.1002/hep.22009Еганян Р. А. Роль неалкогольной жировой болезни печени в развитии сердечно-сосудистых заболеваний. CardioСоматика, 2018, 9, 1, стр. 47–53.Eganyan R. A. The role of non-alcoholic fatty liver disease in the development of cardiovascular diseases. CardioSomatics. 2018;9(1):47–53.

The authors declare that there are no conflicts of interest present.